Wegovy is an anti-obesity drug owned by Novo and is available in a solution for subcutaneous use. This drug contains the active ingredient semaglutide. It has a total of 6 drug patents and none of them have expired yet. Wegovy was first authorized for market use on 04 June, 2021.
The generic release of Wegovy is possible after 17 February, 2041. Specifically, the patent US11318191 titled 'GLP-1 compositions and uses thereof' is expected to expire on 2041-02-17, paving the way for the introduction of Wegovy generic into the market.
Wegovy is mainly used for weight management. Its active ingredient, semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist that contributes to its effectiveness by helping reduce hunger and increase feelings of fullness, which can lead to reduced calorie intake and weight loss.
Wegovy holds several patents with the most significant being 'GLP-1 compositions and uses thereof' with expiry in 2041. This is expected to majorly impact the availability of Wegovy generic. Below are the details of the patent: